These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 8999503)
1. [Determination of free PSA in 85 consecutive cases with increased total PSA]. Rothen JP; Vuillemin R Schweiz Med Wochenschr; 1996 Dec; 126(49):2141-3. PubMed ID: 8999503 [TBL] [Abstract][Full Text] [Related]
2. Increased discrimination between benign prostatic hyperplasia and prostate cancer through measurement of percentage free PSA. Wolff JM; Boeckmann W; Effert PJ; Habib FK; Jakse G Anticancer Res; 1997; 17(4B):2993-4. PubMed ID: 9329583 [TBL] [Abstract][Full Text] [Related]
4. [Free/total prostate specific antigen ratio (%PSA) to predict probability of prostate cancer]. Zenimoto M; Kita M; Arai T; Murayama T; Mori M Rinsho Byori; 2003 Oct; 51(10):969-73. PubMed ID: 14653195 [TBL] [Abstract][Full Text] [Related]
5. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382 [TBL] [Abstract][Full Text] [Related]
6. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma. Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461 [TBL] [Abstract][Full Text] [Related]
7. Two-dimensional electrophoresis of prostate-specific antigen in sera of men with prostate cancer or benign prostate hyperplasia. Charrier JP; Tournel C; Michel S; Dalbon P; Jolivet M Electrophoresis; 1999; 20(4-5):1075-81. PubMed ID: 10344287 [TBL] [Abstract][Full Text] [Related]
8. [Value of free/total prostate specific antigen in the early diagnosis of prostate cancer (study of 105 patients)]. de la Taille A; Houlgatte A; Houdelette P; Berlizot P; Ramirez J; Ricordel I Prog Urol; 1997 Apr; 7(2):240-5. PubMed ID: 9264766 [TBL] [Abstract][Full Text] [Related]
9. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging. Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354 [TBL] [Abstract][Full Text] [Related]
10. The clinical value of the Enzymun-Test for total and free PSA--a multicentre evaluation. Reiter W Anticancer Res; 1999; 19(6C):5559-62. PubMed ID: 10697616 [TBL] [Abstract][Full Text] [Related]
11. [The percentage of free prostate specific antigen used in detecting prostate cancer]. Yang L; Fang Z; Song J; Deng S Zhonghua Wai Ke Za Zhi; 1999 Jan; 37(1):47-9. PubMed ID: 11829778 [TBL] [Abstract][Full Text] [Related]
12. The ratio of free to total prostate specific antigen: an advantageous addition in the differential diagnosis of benign hyperplasia and cancer of the prostate? Reiter W; Stieber P; Schmeller N; Nagel D; Jansen HM; Schambeck C; Fabricius PG; Pahl H; Mattes M; Constabel H; Fateh-Moghadam A Anticancer Res; 1997; 17(4B):2987-91. PubMed ID: 9329582 [TBL] [Abstract][Full Text] [Related]
13. [Prostate-specific antigen as a tumor marker of prostate carcinoma]. Wymenga LF; Mensink HJ Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1733-8. PubMed ID: 10494319 [TBL] [Abstract][Full Text] [Related]
14. Differential diagnosis of prostate cancer and benign prostate hyperplasia using two-dimensional electrophoresis. Charrier JP; Tournel C; Michel S; Comby S; Jolivet-Reynaud C; Passagot J; Dalbon P; Chautard D; Jolivet M Electrophoresis; 2001 May; 22(9):1861-6. PubMed ID: 11425243 [TBL] [Abstract][Full Text] [Related]
15. First clinical results with Enzymun-Test for free PSA. Gilson G; Lamy S; Humbel RL Anticancer Res; 1997; 17(4B):2861-4. PubMed ID: 9329548 [TBL] [Abstract][Full Text] [Related]
16. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis. Lein M; Jung K; Hammerer P; Graefen M; Semjonow A; Stieber P; Ossendorf M; Luboldt HJ; Brux B; Stephan C; Schnorr D; Loening SA Prostate; 2001 May; 47(2):77-84. PubMed ID: 11340629 [TBL] [Abstract][Full Text] [Related]
17. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer? Tarle M; Kraljić I Anticancer Res; 1997; 17(3A):1531-4. PubMed ID: 9179191 [TBL] [Abstract][Full Text] [Related]
18. [The incidence of the variability of the free PSA/total PSA ratio on the early diagnosis of prostate cancer]. de La Taille A; Houlgatte A; Houdelette P; Berlizot P; Fournier R; Ricordel I Prog Urol; 1997 Jun; 7(3):455-63. PubMed ID: 9273075 [TBL] [Abstract][Full Text] [Related]
19. Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia. Paus E; Nilsson O; Børmer OP; Fosså SD; Otnes B; Skovlund E J Urol; 1998 May; 159(5):1599-605. PubMed ID: 9554362 [TBL] [Abstract][Full Text] [Related]
20. Characterization and determination of the complex between prostate-specific antigen and alpha 1-protease inhibitor in benign and malignant prostatic diseases. Zhang WM; Finne P; Leinonen J; Stenman UH Scand J Clin Lab Invest Suppl; 2000; 233():51-8. PubMed ID: 11317942 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]